Overview

Bio Protocol (formerly Bio.xyz) describes itself as “designed to make biotechnology more open, efficient and market-driven, from early-stage funding and liquidity, to milestone-based incentives and agentic automation” — a protocol for directing capital and talent to biotech DAOs ("BioDAOs") and tokenized scientific IP. It incubates and funds specialized BioDAOs, each focused on a specific disease area or scientific domain.

The platform raised over $33 million through Bio Genesis in November 2024, with Binance Labs making its first DeSci investment. In June 2026 it introduced OpenLabs, an AI research hub unveiled at DeSci.Berlin 2026 that folds idea development, contributor coordination and funding into a single interface. Bio Protocol runs the tokenization layer built on Molecule.

The September 2026 repositioning

Between 21 August and 11 September 2026 Bio rebuilt its public site, and the rebuild changed the shop window rather than the mechanism – everything in the two sections below is still documented, and almost none of it is still advertised. Read on 12 September 2026, bio.xyz is titled “Bio / Science for the Network Age” and opens “Bio is where capital, science and intelligence compound”. The terms V2, BioXP, veBIO, Ignition and Liquidity Engine each appear on it zero times – and so does bioDAO, the word this page, Bio's own documentation and the ecosystem it names are all built on. The Internet Archive's 12 June 2026 capture used bioDAO three times and carried a timeline headed “A history of accelerating science onchain”, running from July 2021 to “Q3 2025 – Bio V2” under a YOU ARE HERE marker. Both the timeline and the term are gone; the mechanics they described are not, and docs.bio.xyz still documents V2, BioXP and veBIO in full.

What replaced the timeline is a three-stage loop across five surfaces – explore (BIOS and OpenLabs), fund (Buildspace and the Launchpad) and monetize (Biofy) – which the homepage summarises as “Bio Protocol funds and launches research. BIOS and OpenLabs sit between explore and fund. Biofy turns validated science into products and closes the loop from idea to artefact.” The three new surfaces were probed directly on 12 September 2026 rather than taken from the homepage's description of them, because a named surface behind an HTTP 200 is not evidence that a product exists there:

• OpenLabs is a running product. Its front page is a live feed of posted hypotheses under open peer discussion, the most recent a Nootropics DAO thread on what should count as a credible computational forecast in neuropharmacology, posted the day before. Its own navigation carries Markets, Portfolio, Launchpad, Governance, Bridge and Auctions.
• Buildspace is an intake funnel, not a product. It renders a login gate over the pitch “Get faster funding for your research”, offering “Launch your project” and “Talk to us” and nothing else; its own page description calls it “Bio Protocol's launch pipeline for DeSci projects — from idea through launchpad to milestone-based funding and reporting”. Nothing past the gate is publicly readable, so nothing past it is asserted here.
• Biofy is a shop. Not a metaphor for one: a live storefront taking card payments for physical goods, under the line “From Open Science To Your Body”.

Biofy is the substantive part of the repositioning and the one with the clearest bearing on the rest of this ecosystem, because its shelf is stocked by the BioDAOs themselves. Read on 12 September 2026 it lists six products from three of the organisations this wiki covers: Moon Drops and Sol Drops from DermaLabs (£37.00 each), Creatine Monohydrate, Omega-3 and Magnesium Glycinate from Cerebrum DAO (£25.00, £19.00 and £20.00), and Follicool Shampoo from HairDAO (£22.00, marked down from £24.00). The storefront geolocates its currency, so those figures are what a reader in the United Kingdom is quoted; a Longevity category is listed as “Coming Soon”. For a movement usually assessed on treasuries and token prices, a DeSci protocol selling its member organisations' shampoo and creatine over a conventional checkout is a more legible revenue claim than any of them.

The homepage also publishes three case studies, which are Bio's own figures and are reproduced here as such rather than independently verified: Post-training – “$91,000 bought the first real data. Two rounds later the company runs out of ARK Invest's lab in Florida”; Peptides – “Raised $50,000. Trading fees have paid the project $112,000 so far”, the mechanism being the 70/30 secondary-market fee split described under the Liquidity Engine below; and Hair Loss – “Ten research programmes. Seven patent filings. One product on the shelf at $35 a month”. The three map onto BioAgent post-training work, PeptAI and HairDAO respectively.

One inconsistency is worth recording for anyone reading the documentation as current. The docs' own Bio Protocol concept page still describes Selection as a stage where “BIO token holders participate in selecting which new projects join the ecosystem” and where “selection requires staking BIO tokens to participate”. That is the V1 curation gate, which V2 replaced with the two launch tracks described below; the V2 pages and the concept page disagree, and the V2 pages are the later ones.

A note on this page's own sourcing. Until this revision the Overview described Bio as a “decentralized funding, governance and liquidity engine for early-stage science”, hyperlinked to Bio's documentation. That phrase occurs zero times in Bio's entire published documentation corpus (llms-full.txt, 425 KB, read 12 September 2026) and zero times in the earliest archived copy of the specific page it pointed at, captured 29 April 2025 – a page that is about the DeSci movement generally and has never been Bio's self-description. The link was live, topically plausible and never carried the claim, which is a failure mode no link checker can see. It has been replaced with wording the documentation does carry.

BIO, veBIO and BioXP under Bio Protocol V2

BIO is the protocol's native token, and its 3,320,000,000 supply is a genesis quantity rather than a ceiling. Bio's own token page states that the supply is uncapped, and that new BIO can be minted for future protocol or network growth – with the qualification that doing so would mean deploying a replacement token contract. Nor is 3.32 billion a number any single contract reports. BIO is issued on four chains, and read on 7 September 2026 the four totalSupply() calls return 2,944,100,153 on Ethereum, 183,665,620 on Solana, 182,569,355 on Base and 9,663,740 on BNB Chain: 3,319,998,869 in all, the ~1,132 shortfall being bridge dust.

The genesis allocation, as Bio's own table sets it out, is 25% ecosystem incentives (830,000,000), 21.2% core contributors, 20% community auction, 13.6% investors, 6% community airdrop, 5% to a Molecule-led ecosystem fund, 5% to Molecule itself for transferring core IP, brand and ecosystem stewardship to the Bio.xyz Association, and 4.2% advisors. Ecosystem incentives is the only bucket the table gives no vesting schedule at all – its use is left to a governance vote – while the rest run one-year cliffs on four- to six-year vests, and the community auction is half liquid at launch.

Bio Protocol V2 changed what that token does. The earlier design asked BIO holders to stake on the BioDAOs they wanted admitted, making the token a curation gate on the pipeline. V2 replaced that with two launch tracks: Community Launches, a permissionless track where any team meeting the launchpad's baseline criteria can launch on a standard template, and Curated Launches, a higher-touch track Bio selects into with bespoke tokenomics and post-launch market support. Admission to the permissionless track is no longer something token holders vote or stake a project through.

What the token buys instead is priority. Every launch runs as an Ignition Sale: a fixed price, the same for all participants, denominated in USDC, all-or-nothing against a predefined raise goal – if the goal is not met, every committed dollar is returned. The sales are open to anyone with USDC and carry no BioXP gate; BioXP only decides who gets what when a sale is oversubscribed. A contributor who pledges no BioXP is counted as having pledged 1, the lowest priority weight.

veBIO: a vote-escrow lock that does not yet vote

Staking BIO mints veBIO, a vote-escrowed balance. The lock runs from one week to two years and the weight is veBIO per BIO = weeks remaining in lock / 104, decaying linearly toward the unlock date unless auto-renewal is left on. BIO cannot be withdrawn before the lock expires, and veBIO staking launched on Base only.

The notable detail for anyone reading this as a governance design: veBIO does not currently govern anything. Bio's own documentation states that BIO and vBIO remain the governance tokens of the protocol until veBIO gains sufficient adoption and a formal governance proposal is passed. The escrow is live and accruing benefits while the voting right it is named for is still pending a vote.

Where that vote would be held is named nowhere in Bio's own documentation – its documentation index lists no governance page – and the venue's configuration settles it. The bioxyz.eth Snapshot space weighs a ballot with three erc20-balance-of strategies over exactly the two tokens the docs name as governing: BIO on Ethereum (0xcb15…e5ffA) and on Base (0x226A…77DD2), and vBIO on Ethereum (0x0d2A…D2eF4). The period is three days and the quorum 66,400,000 – exactly 2% of the 3,320,000,000 issued at genesis. V2 itself was ratified there: BIOPSY-24, “Bio Protocol V2 Upgrade – Launchpad, BioXP & Staking”, closed 8 August 2025 with 44 voters. The space has carried 32 proposals in all, and none since BIOPSY-31, “Bridge BIO to BNB”, which closed on 3 November 2025 and was still the most recent proposal when this page was checked on 5 September 2026.

So the “formal governance proposal” that would switch veBIO's voting right on would be the first proposal the space has seen in ten months – and no staker could open it. The space sets onlyMembers, which Snapshot documents as restricting proposals “to authors only” rather than validating a proposer's voting power against a threshold, and that allowlist holds five addresses: two admins and three members. Every BIO or vBIO holder may vote; five addresses decide whether there is anything to vote on. That is an ordinary proposal throttle, and it is also why the quiet cannot be read as holders declining to act – the same distinction that applies to VitaDAO's space and its thirteen-address allowlist, at the same hub. Read as vote-escrow design, veBIO is a lock whose stated unlocking condition is an action only five keys can initiate.

What veBIO does confer today is airdrop exposure. Every new token launched on the platform allocates a share of supply to veBIO holders, distributed pro-rata with no cap and unlocking on an rEUL-style curve: 20% redeemable at TGE, the remaining 80% linearly over six months. Redeeming early permanently forfeits the still-locked remainder of that allocation, which is burned from supply.

BioXP

BioXP is the points layer that sets allocation priority. It is earned by staking BIO, by staking ecosystem assets (IP Tokens, BioAgent tokens and BioDAO tokens), or minted on demand at $0.01 per XP, paid in BIO. Points from BIO staking are credited automatically each day; points from ecosystem-token staking must be claimed manually each day or they expire the next. All BioXP expires 14 days after issue, which Bio describes as a deliberate check on concentration.

Staking an ecosystem token is the looser of the two: no lock duration, but a two-week unstaking cooldown during which points stop accruing immediately, and it yields no vote-escrow token of any kind. BioDAO tokens staked on Base include VITA, HAIR, NEURON, PSY, ATH, CRYO and GROW.

Read as DAO tokenomics, V2 is a deliberate retreat from governance-by-token toward access-by-commitment: the token no longer decides which science gets funded, it decides who gets to the front of the queue when the market wants in.

The Liquidity Engine

The Liquidity Engine is the part of V2 that decides how a funded project keeps getting paid, and it is the clearest break from the one-off treasury raise that most DAOs launched on. Three mechanisms run together.

• Automatic pool seeding. A successful Ignition Sale immediately creates a liquidity pool for the new token. For a standard agent launch, all USDC raised is paired against the token, which accounts for 37.5% of supply. If the project later hits its milestones, a BIO/token pool is added alongside. This is protocol-owned liquidity created at launch rather than rented with emissions.
• Limit-sell fundraising. A reserved share of supply is not handed over at launch. Concentrated liquidity is placed at pre-set fully-diluted-valuation milestones, functioning as standing sell limit orders, and the proceeds unlock to the team only once the token reaches and holds that level for two weeks. Funding tracks sustained market traction rather than launch-day enthusiasm.
• Secondary-market fees. A 1% fee applies to every buy and every sell of the project's token, split 70% to the project treasury and 30% to Bio Protocol. For the project this is continuous non-dilutive revenue; for the protocol it is a claim on the trading volume of everything it launches.

The design has an obvious edge. Tying a team's funding to a two-week-sustained valuation makes the treasury a function of the token chart, which is exactly the coupling AthenaBIO moved away from when it routed institutional capital through an equity vehicle instead, on the reasoning that a freely-traded token price never reflects the value of the underlying science. Bio's answer is not to decouple the two but to make the coupling explicit and milestone-gated.

BioDAO ecosystem

Bio Protocol's own ecosystem listing carried ten BioDAOs when re-read on 12 September 2026, and all ten survived the site rebuild described above word for word: each of the ten one-line descriptions occurs exactly once on the rebuilt page and exactly once in the Internet Archive's 12 June 2026 capture. The listing names none of the ten; it describes them, so the identifications below are made from the descriptions. The eleventh below, DermaLabs, came off the same launchpad – its $SKIN Ignition Sale ran in December 2025 and Bio published its own February 2026 profile of it – but appears in neither capture of that listing, so a count taken off the listing and a count taken off the launchpad's own history do not agree. The BioAgents in the next section are counted separately: they hold a token and a treasury but no voting membership.

• VitaDAO — longevity research (initiated July 2021)
• AthenaBIO — women's health
• PsyDAO — psychedelic science
• ValleyDAO — synthetic biology
• HairDAO — hair-loss research (patents its DAO-funded findings)
• CryoDAO — cryopreservation
• Cerebrum DAO — brain health
• Curetopia — rare diseases
• Long COVID Labs — Long COVID research
• Quantum Biology DAO — quantum biology
• DermaLabs — skincare science

BioAgents

From 2026 the same Launcher also issues BioAgents — autonomous research agents that hold a token and a treasury without a voting membership. Aubrai came first; PeptAI is the one that has published wet-lab confirmation of an agent-designed candidate, and its May 2026 Ignition Sale is the reference example of the mechanism described above.

How Caper approaches this

Bio Protocol is a launchpad: a shared curation-and-funding layer that stands up many BioDAOs, each of which then needs its own token, treasury and governance. A caper is the opposite shape — a single self-contained primitive where the fundraise (a bonding curve), the treasury, the proposal system (PAYOUT / INVEST / DIVEST / METADATA) and a participation-weighted exit ship together. The two are complementary: an ecosystem curator answers "which projects deserve capital"; a caper answers "how does one funded community raise, spend and let members leave without stitching four tools together."

External Links

• Bio Protocol — Official Website
• BIO Token — contract addresses, distribution & unlock schedule (official docs)
• Bio Protocol Documentation
• Bio Protocol V2 - launcher, staking and liquidity engine (official docs)
• The Liquidity Engine - fee split and limit-sell fundraising
• Biofy — Bio's consumer storefront for BioDAO products
• OpenLabs — open hypothesis posting and peer discussion